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In addition to being nutrients, free fatty acids act as signaling
molecules by activating a family of G protein-coupled receptors.
Among these is FFA4, previously called GPR120, which responds
tomedium and long chain fatty acids, including health-promoting
-3 fatty acids, which have been implicated in the regulation of
metabolic and inflammatory responses. Here we show, usingmass
spectrometry, mutagenesis, and phosphospecific antibodies, that
agonist-regulated phosphorylation of the human FFA4 receptor
occurred primarily at five residues (Thr347, Thr349, Ser350, Ser357,
and Ser360) in the C-terminal tail. Mutation of these residues
reduced both the efficacy and potency of ligand-mediated arres-
tin-3 recruitment as well as affecting recruitment kinetics. Com-
bined mutagenesis of all five of these residues was insufficient to
fully abrogate interactionwith arrestin-3, but furthermutagenesis
of negatively charged residues revealed additional structural com-
ponents for the interaction with arrestin-3 within the C-terminal
tail of the receptor. These elements consist of the acidic residues
Glu341, Asp348, and Asp355 located close to the phosphorylation
sites. Receptor phosphorylation thus operates in concert with
structural elements within the C-terminal tail of FFA4 to allow for
the recruitment of arrestin-3. Importantly, these mechanisms of
arrestin-3recruitmentoperate independently fromGq/11coupling,
thereby offering the possibility that ligands showing stimulus bias
could be developed that exploit these differential couplingmecha-
nisms. Furthermore, this provides a strategy for the design of
biased receptors to probe physiologically relevant signaling.
There is growing public, scientific, and medical interest in
the association between diet and well-being. This has been par-
ticularly so in the area of circulating free fatty acids, which are
nutrients necessary to fuel cellular processes but more recently
have been described as bioactive molecules that have direct
impacts on biological processes by interacting with specific cell
surface receptors (1). These free fatty acid receptors have now
been identified as a family of G protein-coupled receptors
(GPCRs),4 FFA1–4, that show selectivity based in part on the
aliphatic chain length of fatty acids (2, 3). Hence, medium and
long chain free fatty acids consisting of 6–12 carbons andmore
than 12 carbons, respectively, activate FFA1 (previously known
as GPR40) and FFA4 (GPR120), whereas the short chain free
fatty acids consisting of less than six carbons (such as acetate,
propionate, and butyrate) activate FFA2 (GPR43) and FFA3
(GPR41) (2, 3). Interest in these receptors has centered on evi-
dence that they play an important role in both metabolic pro-
cesses, in particular glucose homeostasis and lipid metabolism,
and inflammatory responses (4, 5). For this reason, members of
this family of receptors are attractive drug targets for a number
of human disease indications (6–8), in particular type 2 diabe-
tes (9, 10).
Although to date the primary focus has been on the FFA1
receptor to which ligands have been developed and progressed
to clinical trials for type 2 diabetes (9, 10), less is known of the
action of the other fatty acid receptor that is activated by
mediumand long chain free fatty acids, namely FFA4.Although
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responding to the same natural fatty acids as FFA1, such as
linoleic acid and “fish oils,” including -3 fatty acids, FFA4
shows limited sequence identity to the other members of the
FFA family (2, 11). A primary role of FFA4 appears to be in the
regulation of the release of the incretin glucagon-like peptide-1
from enteroendocrine cells in the gut (11). Through this mech-
anism, FFA4 may regulate insulin release and glucose homeo-
stasis, although there is also evidence that FFA4 may be
expressed on pancreatic cells and have a more direct role in
insulin release (12). In addition, FFA4 appears to be expressed
on adipocytes where this receptor is proposed to enhance glu-
cose uptake and on macrophages where it mediates an anti-
inflammatory response (13). Notably, themechanisms of signal
transduction utilized by FFA4 in these different tissues are dis-
tinct, in that G protein signaling via Gq/G11 is the predominant
pathway in enteroendocrine cells and adipose tissue, whereas
the anti-inflammatory effects of FFA4 activation in macro-
phages proceed via the kinase TAK1 that is engaged through an
arrestin-generated scaffold (11). It would therefore appear that
targeting FFA4 would be of potential therapeutic value in the
management of complications arising from obesity, particu-
larly type 2 diabetes, and in the control of inflammation (5).
That this may be important has recently been supported by
studies that have provided a genetic link between a non-synon-
ymous SNP in the human FFA4 coding sequence with the risk
of obesity in man (14).
Until recently, synthetic ligands selectively targeting FFA4
have been lacking, and as such, many studies have been
restricted to the use of various fatty acids that, although the
endogenous ligands, have modest affinity for the receptor. To
provide novel, selective pharmacological tools to probe the
function of FFA4, we recently developed a highly selective
FFA4 agonist, 3-(4-((4-fluoro-4-methyl-[1,1-biphenyl]-2-
yl)methoxy)phenyl)propanoic acid (TUG-891) (15). Impor-
tantly, TUG-891 activates the FFA4 receptor with high
potency, efficacy, and selectivity and in a manner similar to
that of the natural long chain free fatty acids (16). In this
respect, TUG-891 appears to show no stimulus bias and there-
fore is an excellent tool compound to probe the function of
FFA4. Here we used TUG-891 alongside the natural fatty acid
-linolenic acid to explore the potential of FFA4 to be phos-
phorylated and the consequences of this for interaction of the
receptor with arrestin-3 (also designated -arrestin-2). We
demonstrated that human FFA4was phosphorylated in an ago-
nist-sensitive manner on 5 hydroxyl amino acids located in the
C-terminal tail of the receptor. These phosphorylation sites
regulated the effectiveness of interaction of the receptor with
arrestin-3 butwere not the only components of this interaction.
In addition, there were structural elements contributed by
acidic residues within the C-terminal tail that operated in con-
cert with receptor phosphorylation to allow for full recruitment
of arrestin-3. Alteration of these residues or truncation of the
full C-terminal tail did not restrict activation of heterotrimeric
G proteins. In this way, wemade a clear distinction between the
mechanism of coupling to heterotrimeric G proteins and arres-
tin-3 signaling, raising the prospect that ligands can be devel-
oped that selectively activate one of these signaling arms over
the other. We discuss how such ligands showing stimulus bias
might have important clinical benefits.
EXPERIMENTAL PROCEDURES
Materials—Unless otherwise stated all biochemicals and
reagents were from Sigma-Aldrich. TUG-891 was synthesized
as described previously (15).
Plasmids and Mutagenesis—Plasmids encoding human
FFA4 (short isoform) fused at its C terminus to enhanced yel-
low fluorescent protein (eYFP) and incorporating an N-termi-
nal FLAG epitope and arrestin-3 fused to Renilla luciferase
(Rluc) were as described previously (15). To generate a C-ter-
minal HA epitope-tagged form of FFA4, the receptor coding
sequence was amplified by PCR using the forward (5-TTT-
TAAGCTTGCCACCATGTCCCCTGAATGCGC-3) and
reverse (5-TTTTGGATCCTTAAGCGTAATCTGGAACA-
TCGTATGGGTAGCCAGAAATAATCGACAAGTCA-3)
primers, which incorporated theHA tag sequence followed by a
stop codon immediately following the final codon of FFA4. This
PCR product was then inserted into the HindIII and BamHI
sites of pcDNA5 FRT/TO. To generate FFA4 truncations, the
FLAG-FFA4 sequence was amplified from the FLAG-FFA4-
eYFP plasmid using the forward primer 5-TGCTAAGCTTC-
TTGCCACCATGGACTA-3 combined with a reverse primer
for each truncation as follows: 336, 5-AAAGGTACCGCAG-
CAAAAAATTTTCTTCCA-3; 340, 5-TTTTGGTACCTG-
GGAACCAGAAGCAGCA-3; 345, 5-AAAAGGTACCAAT-
GGCTCCCTTTTCTGGG-3; 350,5-AAAGGTACCAGAT-
GTGTCTGTTAAAATGGC-3; and 355, 5-AAAGGTACCG-
TCATTTCTTTTGACAGATGT-3. Each PCR product was
then inserted into the pcDNA5 FRT/TO vector immediately
before the coding sequence for eYFP. Mutations to the FFA4
sequence were incorporated using the QuikChange method
(Stratagene, Cheshire, UK), and the identities of all plasmids
generated were confirmed through sequencing.
Stable Cell Lines—Stable inducible Flp-InTM T-RExTM cells
were generated by co-transfecting FLAG-FFA4-eYFP, FLAG-
FFA4-TSS/AAA-eYFP, or FLAG-FFA4-340-eYFP with the
pOG44 plasmid into parental Flp-In T-REx cells (Life Technol-
ogies). Following transfection, hygromycin B was added to the
culture medium allowing for polyclonal selection of stable cell
lines that inducibly expressed the receptor of interest in
response to the antibiotic doxycycline.
Chinese hamster ovary (CHO) cells that stably and constitu-
tively expressed the C-terminal HA epitope-tagged FFA4 or
FFA4 containing mutations within the C-terminal tail were
generated using the Flp-In system. CHO Flp-In cells were co-
transfected with pcDNA5FRT containing FFA4 and pOG44,
transfected cells were selected with hygromycin B, and expres-
sion of FFA4 was confirmed by immunoblotting with anti-HA
antibodies.
[32P]Orthophosphate Labeling and FFA4 Immunoprecipita-
tion—Cells were plated in 6-well plates at 200,000 cells/well
24 h before experimentation. For phosphorylation experi-
ments, cells were washed three times with Krebs/HEPES buffer
without phosphate (118 mM NaCl, 1.3 mM CaCl2, 4.3 mM KCl,
1.17 MgSO4, 4.17 mM NaHCO3, 11.7 mM glucose, 10 mM
HEPES (pH 7.4)) and incubated in this buffer containing 100
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Ci/ml [32P]orthophosphate for 1 h at 37 °C. Cells were stimu-
lated for 5 min with test compounds and immediately lysed by
addition of buffer containing 20 mM Tris (pH 7.4), 150 mM
NaCl, 3 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate. FFA4 was immunoprecipitated from the cleared
lysates using anti-HA affinity matrix (Roche Applied Science).
Thewashed immunoprecipitateswere separated by SDS-PAGE
on 10% gels that were dried, and radioactive bands were
revealed using autoradiography film. The films were scanned,
and bands were quantified using AlphaImager software (Alpha
Innotech, San Leandro, CA).
FFA4 Purification and Mass Spectrometry—Stably trans-
fectedCHOcells expressing FFA4HA-tagged at theC terminus
were grown until confluent in expanded surface rolling bottles
at 0.25 rpm in a humidified CO2 incubator. For receptor puri-
fication, cells from four rolling bottles were harvested, resus-
pended in 40 ml of Krebs/HEPES buffer, and stimulated with
TUG-891 (10 M) for 5 min. Membranes were then prepared
and solubilized by addition of 5 ml of PBS containing 1% Non-
idet P-40 plus amixture of protease and phosphatase inhibitors
(Roche Applied Science). After centrifugation at 20,000  g,
the resulting supernatant was diluted 1:1 with PBS, and the
receptor was then purified on anti-HA affinity matrix. After
extensive washing with solubilization buffer containing 0.5%
Nonidet P-40, the resin was resuspended in 2 SDS-PAGE
sample buffer. The sample was resolved by SDS-PAGE on
10% gels and stained with colloidal Coomassie Blue. Purified
FFA4 receptors were excised from the polyacrylamide and
washed three times for 15 min with 100 mM triethylammo-
nium bicarbonate (TEAB). Reduction and alkylation of cys-
teines were performed by addition of 10mMdithiothreitol in 50
mM TEAB at 60 °C for 30 min followed by addition of 100 mM
iodoacetamide in 50mMTEAB for 30min in the dark. Gel slices
were washed three times for 5 min with 50 mM TEAB contain-
ing 50% acetonitrile, finally resuspended in TEAB containing
10% acetonitrile, and incubated overnight at 37 °C with 1 g of
sequencing grade trypsin (Promega, Southampton, UK).
The resulting tryptic peptides were dried and resuspended in
1 ml of buffer containing 250 mM acetic acid and 30% acetoni-
trile, and phosphorylated peptides were enriched by addition of
20 l of PHOS-SelectTM iron affinity resin and incubation at
room temperature for 2 h with mixing. After washing resin
twicewith loading buffer and oncewithwater, tryptic phospho-
peptides were eluted by addition of 200 l of buffer containing
400 mM ammonium hydroxide and 30% acetonitrile.
LC-MS/MS was carried out upon each sample using an LTQ
Orbitrap mass spectrometer (Thermo Fisher Scientific, Rock-
ford, IL). Peptides resulting from in-gel digestionwere loaded at
high flow rate onto a reverse-phase trapping column (0.3-mm
inner diameter  1 mm) containing 5-m C18 300-Å Acclaim
PepMap medium (Dionex, UK) and eluted through a reverse-
phase capillary column (75-m inner diameter  150 mm)
containing Symmetry C18 100-Å medium (Waters, Elsetree,
UK) that was self-packed using a high pressure packing device
(Proxeon Biosystems, Odense, Denmark).
The resulting spectra were searched against the UniProtKB/
Swiss-Prot database using Mascot (Matrix Science Ltd.) soft-
ware with peptide tolerance set to 5 ppm and the MS/MS tol-
erance set to 0.6 Da. Fixed modifications were set as
carbamidomethylcysteine with variable modifications of phos-
phoserine, phosphothreonine, phosphotyrosine, and oxidized
methionine. The enzyme was set to trypsin/proline, and up to
two missed cleavages were allowed. Peptides with a Mascot
score greater than 20 and for which the probability p that the
observed match was a random event was0.05 were included
in the analysis. The spectra of peptides reported as being phos-
phorylated were interrogated manually to confirm the precise
sites of phosphorylation.
Generation of Glutathione S-Transferase (GST) Fusion
Constructs—Human FFA4 C-terminal residues Asn317–Gly361
were inserted into pLEIS 50 to produce C-terminal GST
fusions. Escherichia coli BL21(DE3) IRL transformed with the
fusion constructs or pGEX-2t alone were grown in LBmedium
containing 50 g/ml ampicillin, 50 g/ml chloramphenicol,
and 1% (w/v) glucose, and protein expression was induced by
addition of isopropyl 1-thio--D-galactopyranoside to a final
concentration of 100 M.
Generation of Phosphorylation-specific FFA4 Antiserum—A
phosphorylation-specific antiserumwas raised against the pep-
tide KGAILT(P)DTS(P)VKR, which corresponds to amino acids
342–353 of human FFA4 inwhich threonine 347 and serine 350
were phosphorylated. The 87-day program, which included
four immunizations, was performed by Eurogentec (Leige Sci-
ence Park, Seraing, Belgium). The resulting antiserumwas puri-
fied against the immunizing peptide.
Immunocytochemistry—CHO cells expressing FFA4 HA-
tagged at the C terminus were seeded onto 20-mm glass cover-
slips for 24 h prior to experimentation. Cells were washed and
incubated for 1 h in Krebs/HEPES buffer prior to treatment.
Cells were fixed in PBS containing 4% paraformaldehyde and
0.1% glutaraldehyde for 30 min at room temperature. Anti-HA
antibody was used at 5 ng/ml followed by Alexa FluorTM 546
goat anti-rat secondary antibody at 1:1000 dilution. Data were
acquired using anLSM510 laser-scanning confocalmicroscope
(Zeiss).
FFA4/Arrestin-3 Interaction Assay—To assess arrestin-3
recruitment to FFA4, a bioluminescence resonance energy
transfer (BRET) assaywas used based on our protocol described
previously (15). Briefly, HEK293T cells were co-transfected
with arrestin-3-Rluc and FLAG-FFA4-eYFP plasmids in a 1:4
ratio using polyethyleneimine.After 24-h incubation, cells were
subcultured into poly-D-lysine-coated white 96-well micro-
plates and incubated for a further 24 h prior to the assay. Cells
were then washed with Hanks’ balanced salt solution and incu-
bated in Hanks’ balanced salt solution for 30 min prior to con-
ducting the assay. To initiate the assay, the Rluc substrate coel-
enterazine h was added to a final concentration of 2.5 M and
incubated for 10 min at 37 °C before the test compound was
added. Following a further 5-min incubation, luminescence
emissions at 535 and 475 nm were measured using a
PHERAstar FS (BMG Labtech, Offenburg, Germany), and the
BRET signal was represented as the 535/475 ratiomultiplied by
1000 to yield the arbitrary milli-BRET units. For all mutant
forms of FFA4, the BRET signals obtained are expressed as a
percentage of the maximum milli-BRET units obtained for
TUG-891 at the wild type receptor. To conduct kinetic arres-
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tin-3 recruitment experiments, cells were incubated at 37 °C in
the PHERAstar FS after coelenterazine h had been added, and
BRETmeasurementswere taken at 6-s intervals. In these exper-
iments, test compound was added using PHERAstar FS injec-
tors, allowing for continuous measurement during and imme-
diately following compound addition.
Mobilization of Intracellular Ca2—Intracellular Ca2
measurements were taken from Flp-In T-REx 293 cells induced
to express the receptor of interest by treatment with 100 ng/ml
doxycycline according to a protocol described previously (16).
All data are represented as a percentage of the maximum
response obtained for TUG-891 within the same cell line.
High Content Imaging Quantitative Internalization Assay—
Quantitative measurements of FFA4 internalization in Flp-In
T-REx 293 cells induced to express the receptor of interest with
100 ng/ml doxycyclinewere taken using a high content imaging
system following our protocol described previously (16). For
these experiments, quantification was based on the intensity of
eYFP fluorescence observedwithin internalized spots while cell
numberwas controlled for using aHoechst nuclear stain.As the
signal measured in this assay system is strongly dependent on
receptor expression level, estimates comparing the efficacy of
internalization between different cell lines were not made.
Therefore data are represented as a percentage of the maxi-
mum response obtained for TUG-891 within the same cell line
except for the FFA4-340 truncation, which is expressed as a
percentage of the response in the wild type cells as TUG-891
had no measurable effect on this receptor variant.
Data Analysis and Curve Fitting—All data presented repre-
sent means  S.E. of at least three independent experiments.
Data analysis and curve fitting were carried out using the
GraphPad Prism software package. Concentration-response
data were plotted on a log axis where the untreated vehicle
control conditionwas plotted at 1 log unit lower than the lowest
test concentration of ligand and fitted to three-parameter sig-
moidal concentration-response curves. Statistical analyses
were carried out using standard t tests, one-way analysis of vari-
ance with Tukey’s post hoc analysis, or two-way analysis of
variance combined with Bonferroni post hoc analysis as
appropriate.
RESULTS
Agonist-promoted Phosphorylation of FFA4
We have previously described key signaling responses of the
FFA4 receptor following stimulation with the natural fatty acid
agonist-linolenic acid and the FFA4-selective chemical ligand
TUG-891 (16). These included enhanced phosphorylation of
the receptor as monitored by increased incorporation of 32P
into a polypeptidewith an apparentmolecularmass between 45
and 50 kDa in CHO cells stably expressing HA-tagged human
FFA4 (Fig. 1A). Enhanced incorporation of 32P into polypep-
tide(s) with an apparent molecular mass of some 100 kDa was
also observed (Fig. 1A). These may represent either dimeric
complexes of FFA4 or themonomeric receptor in complexwith
other protein(s) of similar molecular mass.
To investigate the details of ligand-promoted phosphoryla-
tion of this receptor, we conducted a mass spectrometry-based
proteomics study to determine the precise sites of phosphory-
lationwithin FFA4. In these experiments, HA-tagged FFA4was
purified following stimulation with TUG-891 (10 M; 5 min).
Mass spectrometry-based proteomic analysis of tryptic pep-
tides generated from the isolated FFA4 revealed excellent pep-
tide coverage of the third intracellular loop and C-terminal tail
(Fig. 1). Importantly, this included peptides that contained 11 of
the 16 serine and threonine residues within these intracellular
domains. MS/MS sequencing revealed four phosphorylation
sites (Thr347, Thr349, Ser350, and Ser357), all of which were
located in the C-terminal tail (Fig. 1, B–E). Recombinant CHO
cells were generated that stably expressed mutant FFA4 recep-
tors in which these phosphorylation sites were mutated to ala-
nine residues.We initiallymutated Thr347, Ser350, and Ser357 to
alanine in a mutant designated TSS/AAA (Fig. 2A). Phosphor-
ylation of this mutant in response to TUG-891 was reduced by
74.4 3.0% (n 3) (Fig. 2,B andC). Furthermutation of Thr349
to generate the mutant TTSS/AAAA removed all the phosphor-
ylation sites identified by mass spectrometry (Fig. 2A). This
mutant still showed some agonist-regulated phosphorylation
but markedly less than the TSS/AAA mutant (Fig. 2, B and C).
The only other possible serine/threonine phosphorylation site
in the C-terminal tail of FFA4 was Ser360. This residue was
mutated in combination with Thr347, Thr349, Ser350, and Ser357
to generate the mutant TTSSS/AAAAA (Fig. 2A). No evidence
of agonist-regulated phosphorylation was seen for this mutant
(Fig. 2, B and C), indicating that the sites of agonist-regulated
phosphorylation in FFA4 were Thr347, Thr349, Ser350 Ser357,
and Ser360.
Characterization of Phosphospecific Antibodies
Phosphospecificantibodieswereraisedtoadoublyphosphor-
ylated peptide containing phosphates on residues correspond-
ing to Thr347 and Ser350 of FFA4. This phosphopeptide was
chosen because there was good evidence from the mass spec-
trometry studies that these residues were phosphorylated
simultaneously and because this doubly phosphorylated pep-
tide was predicted to be highly immunogenic. The antiserum
generated from the immunization was subjected to affinity
purification that resolved phosphospecific antibodies from
non-phosphospecific antibodies (described herein as “struc-
tural” antibodies). To test the specificity of the antibodies, a
GST bacterial fusion protein containing the final 45 amino
acids of the C-terminal tail of FFA4 was prepared. Because bac-
teria do not generally phosphorylate mammalian fusion pro-
teins, the FFA4-C-tail fusion protein acted as a negative control
for the phosphospecific antibodies in immunoblots of bacterial
lysates containing this protein (Fig. 3A). The FFA4-C-tail
fusion protein was readily identified in immunoblots using a
commercial antibody against GST (Fig. 3B) and by the struc-
tural FFA4 antibodies (Fig. 3C) but was not detected with the
putative phosphospecific antibody fraction (Fig. 3D). However,
the phosphospecific FFA4 antibody fraction readily detected
FFA4 expressed in CHO cells in a manner that was up-regu-
lated by 1.8-fold in response to acute treatment with either
-linolenic acid or TUG-891 (Fig. 3, E and F). Importantly, the
band corresponding to phosphorylated FFA4 in immunoblots
of transfected cell extracts was absent in lysates prepared from
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control non-transfected CHO cells (Fig. 3E). The phosphospe-
cific FFA4 antibodies also effectively identified a C-termi-
nally eYFP-tagged form of FFA4 transiently expressed in
HEK293T cells with, once again, marked increases in detec-
tion of the receptor following treatment of the cells with
TUG-891 for various times (Fig. 3G), indicating that FFA4
phosphorylation appears to operate in a similar manner in
both CHO cells and HEK293 cells.
Agonist-regulated Phosphorylation of FFA4 Is Not via Protein
Kinase C (PKC)
To investigate the possibility that PKC isoformsmightmedi-
ate agonist-regulated FFA4 phosphorylation, experimentswere
performed using 32P labeling and immunoblotting with the
phosphospecific antibodies. Treatment of cells with the phor-
bol ester phorbol 12-myristate 13-acetate for 10min resulted in
global phosphorylation of FFA4 that was significantly greater
than basal (Fig. 4, A and B). This suggested that PKC canmedi-
ate heterologous phosphorylation, consistent with previous
observations (17, 20). However, agonist-dependent phosphor-
ylation was not PKC-mediated because pretreatment of cells
with bisindolylmaleimide II, a PKC inhibitor, for 10min did not
decrease the levels of agonist (TUG-891)-dependent phosphor-
ylation (Fig. 4, A and B). Importantly, in control experiments,
bisindolylmaleimide II pretreatment did inhibit phorbol
12-myristate 13-acetate-mediated phosphorylation (Fig. 4, A
FIGURE 1. Mass spectrometry identifies four distinct sites of phosphorylation in FFA4. CHO cells stably expressing C-terminally HA-tagged FFA4
were either labeledwith 32P (A) or used to immunoprecipitate and then digest the receptor for analysis usingmass spectrometry (B–E). In the 32P labeling
studies, cells were treated with the agonist TUG-891 (10 M) or vehicle for 5 min prior to sample preparation. An autoradiogram (upper panel) and
loading control representing an anti-HA immunoblot of the same samples (lower panel) are shown from a representative experiment. B–D, represent-
ative mass spectra and associated fragmentation tables are shown that cover the four phosphorylated residue, Thr347, Thr349, Ser350, and Ser357
identified in various experiments (noted in bold are the 3rd intracellular loop and C-terminal tail within the primary sequence of FFA4, underlined
sections represent FFA4 peptides observed in mass spectrometry experiments and in red are amino acids identified as being phosphorylated). E, a
summary of the overall data set.
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and B). Interestingly, the cells were serum-starved overnight
in these experiments, which appeared to reduce the basal
phosphorylation.Forthisreason, the-fold increase inphosphor-
ylation observed in this series of experiments is higher than
reported for our other experiments (e.g. in Figs. 2 and 3).
Incontrast toapreviousstudy (20),PKCdidnotappear tomedi-
ate phosphorylation ofThr347 and Ser350when tested in immuno-
blot experiments using the phosphospecific antibodies recogniz-
ing these sites (Fig. 4, C and D). These experiments were carried
out again on serum-starved cells and with a 1M phorbol 12-my-
ristate 13-acetate concentration equivalent to that used by Burns
et al. (20). Thus, our studies demonstrate that, although PKC has
the potential to phosphorylate FFA4 and that FFA4 is Gq/11-cou-
pled and therefore able to signal through PKC, there does not
appear to be a feedback loop where PKC can further phosphor-
ylate the receptor following agonist stimulation.
Arrestin-3 Interaction with the C-terminal Tail of FFA4
FFA4 interacts effectively with arrestin-3 in an agonist-de-
pendent manner (16). To begin to dissect the potential role of
the C-terminal tail of FFA4 in the regulation of receptor signal-
ing, we truncated the receptor following residue 336 immedi-
ately after the pair of Cys residues that are likely to be palmi-
toylated and define the end of the putative intracellular helix 8.
In addition, we generated a series of less extensive truncations,
the first of which after Asp355, removing the final 6 amino acids
of FFA4, and then in 5-amino acid blocks up to Pro340 (Fig. 5A).
When tested in a BRET-based arrestin-3 interaction assay, 5
min of TUG-891 (10M) treatment yielded a strong increase in
arrestin-3-Rluc/FFA4-eYFP BRET, increasing the basal signal
of 63 6milli-BRETunits to theTUG-891-stimulated signal of
399 19 milli-BRET units. Extending these studies to also test
the truncations demonstrated that these forms produced clear
reductions in BRET signal that correlated with the extent of
FFA4 truncation (Fig. 5B). Specifically, although signals for 336
and 340 truncations were all but absent, those to residues 345,
350, and 355 showed increasing BRET response efficacies that
were measured to be 25  2, 64  4, and 73  4% of the wild
type FFA4 signal, respectively.
To explore the contribution of the FFA4 C-terminal tail in
more detail, we chose to focus on the FFA4-340 variant as the
FIGURE2.Mutational analysis of FFA4 confirms these four sites of agonist-inducedphosphorylationand identifies a further site. 32P labeling studies of
FFA4 were performed as detailed in Fig. 1 using CHO cells stably expressing either wild type HA-tagged FFA4 or the various mutants illustrated in A. B, an
autoradiogram (upper panel) and loading control representing an anti-HA immunoblot of the same samples (lower panel) from a representative experiment.
TUG-891 was added where specified for 5 min. C, quantification of studies akin to those shown in B (mean S.E.; n 3). Error bars represent S.E.
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FIGURE3.Characterizationanduseof anFFA4phosphospecific antiserum.Anantiserumwas raised to identify Thr(P)347,Ser(P)350within theC-terminal tail
of humanFFA4 (see “Experimental Procedures” fordetails). AGST fusionprotein containing the final 45aminoacidsof theC-terminal tail of FFA4wasgenerated
and expressed in E. coli in a manner dependent upon addition of isopropyl 1-thio--D-galactopyranoside (IPTG). Coomassie Blue stain (A) and an anti-GST
immunoblot (B) of SDS-PAGE-resolved lysates of suchbacteria are shown. Following chromatographyover a columncontaining the Thr(P)347,Ser(P)350 peptide
antigen, serum that was not retained (potential anti-FFA4 non-phosphostate-dependent structural antibodies) was separated from antibodies that were
retained (potential anti-FFA4 phosphospecific antibodies). These (C, structural; D, phosphospecific) were used in immunoblots of the samples described in A
and B. Lysates of non-transfected (NT) CHO cells and those expressing FFA4-HA that were exposed to -linolenic acid (aLA) or TUG-891 as indicated were
resolved and immunoblotted with the phosphospecific antibodies (E, upper panel). Loading controls (E, lower panel) represent the same samples immuno-
blotted to detect the HA tag. Such immunoblots were quantified (F). Data represent quantification of experiments shown in E (mean S.E.; n 3).G, HEK293T
cells were transiently transfected to express FFA4-eYFP and subsequently treated for the indicated timeswith TUG-891 (10M). Membrane preparationswere
resolved by SDS-PAGE and immunoblotted with the phosphospecific anti-FFA4 antibodies. Error bars represent S.E.
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least extensive truncation for which interaction with arrestin-3
was effectively eliminated. To first confirm that arrestin-3
interactionwas eliminated in thismutant, kinetic BRET studies
were carried out and demonstrated that even with up to a
20-min treatment TUG-891 was unable to stimulate arrestin-3
interaction with FFA4-340 (Fig. 5C). This lack of agonist-in-
duced interaction with arrestin-3 also correlated with a lack of
agonist-induced internalization of the truncated FFA4-340
mutant (Fig. 5D). Although these data demonstrate the essen-
tial nature of the C-terminal tail of FFA4 for arrestin-3 interac-
tion and internalization, a concentration-dependent (pEC50
6.10 0.13) calciummobilization in response toTUG-891with
similar potency to wild type FFA4 (pEC50  6.28  0.05) was
maintained for the FFA4-340 C-terminal tail truncation (Fig.
5E), indicating that the distal C terminus beyond the putative
intracellular helix 8 is not required for acute Gq/11 coupling of
FFA4. Thus, FFA4 displayed classical GPCR bimodal signaling
properties where one arm consists of agonist-mediated inter-
action with arrestins in a process that drives arrestin-depen-
dent mechanisms, including receptor internalization, and the
other arm independently couples the receptor to heterotri-
meric G proteins and G protein-mediated signaling pathways
(e.g. calcium mobilization) (18).
Structural and Phosphorylation-dependent Elements Combine
to Regulate FFA4/Arrestin-3 Interaction
Phosphorylation-dependent Arrestin-3 Interaction—A num-
ber of the C-terminal truncations eliminated amino acids that
become phosphorylated in an agonist-dependent manner. To
establish the importance of phosphorylation in the interaction
of FFA4with arrestin-3, the FFA4mutant designatedTSS/AAA
containing alanine substitutions in three of the phosphoryla-
tion sites (Thr347, Ser350, and Ser357), which resulted in a 74%
reduction in agonist-mediated phosphorylation (Fig. 2B), was
used in arrestin-3 recruitment assays. These experiments dem-
onstrated that the mutant receptor showed a significant
decrease in both potency (for TUG-891 at wild type FFA4,
pEC50 7.23 0.08, and for FFA4-TSS/AAA, pEC50 6.85
0.11; p 0.05) and efficacy (77 2% of wild type response; p
0.001) for arrestin-3 recruitment measured after 5 min in the
BRET assay (Fig. 6A). Extending the time course of measure-
ment demonstrated that the TSS/AAAmutant showed a slow-
ing in the kinetics of associationwith arrestin-3: wild type FFA4
interacted with arrestin-3 with a t1⁄2 of 46 6 s, and FFA4-TSS/
AAA interacted with arrestin-3 with a significantly longer (p
0.001) t1⁄2 of 121 10 s (Fig. 6B). This was linked to a disruption
FIGURE 4. PKC can phosphorylate FFA4 but does not contribute to TUG-891-mediated phosphorylation of Thr(P)347 and Ser(P)350. CHO cells as in Fig.
3E were used in 32P labeling experiments as detailed in Fig. 1. Cells were exposed to phorbol 12-myristate 13-acetate (PMA), bisindolylmaleimide II (BIS II),
TUG-891, or combinations of these as detailed. Subsequently, cell lysates were subjected to immunoprecipitation with anti-HA antibodies and resolved by
SDS-PAGE, and autoradiography was performed. A represents a representative autoradiogram, and B represents quantification of incorporation of 32P into
FFA4 in such experiments. C and D are equivalent experiments in which the cell lysates were probed with the dual Thr(P)347,Ser(P)350 phosphospecific
antibodies (data in B and D represent means S.E.; n 3). Error bars represent S.E. **, p 0.01; ***, p 0.001.
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of agonist-mediated receptor internalizationwhere FFA4-TSS/
AAA showed a significant (p 0.05) decrease in the potency for
TUG-891 to stimulate receptor internalization (pEC50 
5.81 0.22 comparedwith 6.68 0.11 forwild type FFA4) (Fig.
6C) and a significantly reduced time course for internalization
(Fig. 6D). This disruption in receptor internalization was also
evident in CHO cells stably expressing forms of HA-tagged
FFA4. Here anti-HA immunostaining indicated a predomi-
nantly plasma membrane and uniform localization for both
wild type FFA4 and FFA4-TSS/AAA (Fig. 6E, yellow arrows)
under basal conditions, whereas following addition of TUG-
891, a more punctate membrane distribution and intracellular
vesicle-like staining became apparent (Fig. 6E, white arrows) in
cells expressing wild type FFA4 (Fig. 6E). These changes in
membrane distribution and the appearance of receptor in intra-
cellular vesicles were less evident but not absent in cells
expressing the phosphorylation-limitedTSS/AAAmutant (Fig.
6E).
To further probe the role of phosphorylation, mutations to
eliminate the other sites of phosphorylation were made. Inter-
estingly, mutating Thr349 in addition to the TSS/AAA muta-
tions (to generate the mutant TTSS/AAAA) did not have a
significant further impact on arrestin-3 recruitment efficacy
(Emax 77 2% for TSS/AAA, and Emax 84 7% for TTSS/
AAAA) (Fig. 7A). This is despite the fact that the TTSS/AAAA
mutant showed less phosphorylation in response to agonist
than theTSS/AAAmutant (Fig. 2,B andC). This suggested that
it is not necessarily only the bulk negative charge at the C-ter-
minal tail of the receptor resulting fromphosphorylation that is
important for the arrestin-3 recruitment signal but also the spe-
cific location of the negative charge. In support of this notion,
adding mutation of Ser360 to FFA4-TSS/AAA to generate the
mutant TSSS/AAAA did significantly (p  0.001) further
reduce arrestin-3 recruitment efficacy (38  2%) (Fig. 7A).
Finally, combining the Thr349 and Ser360 mutations to gen-
erate the complete phosphorylation-negative TTSSS/AAAAA
mutant (Fig. 2B) resulted in a BRET response of 42 2%, which
was significantly reduced compared with either TSS/AAA or
TTSS/AAAA (p  0.001) but was not significantly different
from the response to the TSSS/AAAAmutant (Fig. 7A). These
experiments indicated that phosphorylation sites Thr347,
Ser350, Ser357, and Ser360 contribute to arrestin-3 recruitment
FIGURE 5. Truncation of elements of the C-terminal tail of FFA4 limits agonist-induced interaction with arrestin-3 but not Ca2 signaling potency. A
series of truncation constructs of FFA4were generated and linked in-frame to eYFP. A, numbers and lines highlight the final amino acid in each truncation, and
the sites of agonist-mediated phosphorylation identified directly by mass spectrometry (Fig. 1) are bold. B, wild type FFA4-eYFP and each of the truncations
were then used in BRET-based arrestin-3 interaction assays after transient co-expression inHEK293T cellswith Rluc-tagged arrestin-3. Concentration-response
curves for TUG-891 to promote FFA4/arrestin-3 interaction at each truncation are displayed. C, extending the measurement time to 20 min (10 M TUG-891)
indicates that the FFA4-340 truncation still does not interact with arrestin-3.D, normalized high content imaging internalizationmeasurements in response to
TUG-891 suggest that FFA4-340 does not internalize. Data are shown for FFA4-eYFP and FFA4-340-eYFP expressed stably in Flp-In T-REx 293 cells. Wild type
FFA4-eYFP yielded a raw signal window between 99 9 arbitrary fluorescence units/cell in unstimulated cells and 603 44 arbitrary fluorescence units/cell
in TUG-891-treated cells, whereas FFA4-340 yielded values of 38  3 and 44  3 arbitrary fluorescence units/cell for untreated and TUG-891-treated cells
respectively. E, thepotency of TUG-891 to elevate [Ca2]i in acute signaling studies is unaffectedby the FFA4-340C-terminal tail truncation. These experiments
yielded raw Fura 2 ratio signals of 0.03 0.02 and 1.52 0.08 for basal and TUG-891 (10M)-stimulatedwild type FFA4, respectively, and values of 0.09 0.02
and 0.88 0.02 for basal and TUG-891 (10 M)-stimulated FFA4-340, respectively. Error bars represent S.E.
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and that Thr349 appears to play a less significant role, indicating
that theremay be some redundancy in this cluster of phosphor-
ylation sites (Fig. 7A). Importantly, mutating each site individ-
ually had little impact on arrestin-3 recruitment with only the
S360A mutant showing a significant (p  0.001) but relatively
small reduction in efficacy to 85  1% of wild type FFA4
response (Fig. 7B). These data indicate that there is no “master”
phosphorylation event and that it is likely an ensemble of phos-
phorylation events that regulate the phosphorylation-depen-
dent component of FFA4/arrestin-3 interaction and arrestin-3-
dependent processes, including receptor internalization.
Structural Components Also Regulate FFA4/Arrestin-3
Interaction—The above studies indicated a role for agonist-me-
diated receptor phosphorylation in arrestin-3 recruitment to
FFA4. However, removal of all the sites of phosphorylation (i.e.
mutant TTSSS/AAAA) did not eliminate arrestin-3 recruit-
ment in response to agonist (Fig. 7A). This indicated that fac-
tors in addition to receptor phosphorylationmust contribute to
FIGURE 6. Mutation of key sites of agonist-regulated phosphorylation reduces the potency and efficacy of TUG-891 to promote interactions with
arrestin-3andslows thekineticof theprocess.A, comparisonof arrestin-3 interactionTUG-891concentration responses forwild typeFFA4and theTSS/AAA
mutant at a 5-min measurement time point. B, the kinetics of FFA4/arrestin-3 interaction are compared with those of the TSS/AAA mutant. C, TUG-891
concentration responses for FFA4 and FFA4-TSS/AAA internalization measured after 45-min ligand treatment. D, the kinetics of FFA4 and FFA4-TSS/AAA
internalization are shown following treatment with 10 M TUG-891. *, p 0.05; ***, p 0.001 compared with wild type response at the same time point. E,
following stable expression in CHO cells of wild type, TSS/AAA, and TTSSS/AAAAA, HA-tagged FFA4 is present predominantly at the cell surface as detected by
anti-HA immunocytochemistry. Following exposure to TUG-891 (10M) for 30min, the extent of internalization of the TSS/AAA and TTSSS/AAAAAmutants is
substantially lower than forwild type.Yellowarrows illustrate cell surface receptor, andwhite arrowshighlight internalized receptor. Scale bars, 10m.Error bars
represent S.E.
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FFA4/arrestin-3 interaction. To investigate this, additional
mutations were generated to define potential structural ele-
ments on FFA4 that might regulate arrestin-3 interaction.
The initial focus centered on the negative charges contrib-
uted by theAsp residues, Asp348 andAsp355, as Asp residues are
often utilized as “phosphomimetics” and might combine with
the negative charges produced by phosphorylation of nearby
phosphoacceptor sites to further promote arrestin-3 interac-
tion. Indeed, our FFA4 truncation data appeared to support this
hypothesis as a significant increase in arrestin-3 interaction
efficacy (p  0.05) was observed for FFA4-355 (73  4%) over
FFA4-350 (63  4%) despite the fact that this block of amino
acids contains no phosphorylation sites but does possess anAsp
at position 355 (Fig. 5B). To test the role of Asp348 and Asp355,
alanine mutations of these sites individually and in combina-
tion (DD/AA) were incorporated into wild type FFA4. When
tested in the BRET assay, none of these mutations significantly
reduced FFA4/arrestin-3 response efficacy (Fig. 8A). However,
when these mutations were incorporated into the phosphory-
lation-deficient FFA4-TSS/AAA, bothTSS/AAA-D348A (60
6%; p 0.05) and TSS/AAA-D355A (52 3; p 0.001) signif-
icantly reduced efficacy compared with TSS/AAA (77  2%)
(Fig. 8B). Combining these mutations to make the TSS/AAA-
DD/AA mutant resulted in a further reduction in efficacy to
40  1% (Fig. 8B). The impact of Asp348 and Asp355 mutation
was also apparent in the complete phosphorylation-negative
mutant because removing these aspartate residues in the FFA4-
TTSSS/AAAAA mutant to generate the TTSSS/AAAAA-
DD/AA mutant also significantly (p 0.001) reduced the effi-
cacy of interactionwith arrrestin-3 (Emax 42 2% forTTSSS/
AAAAA, and Emax  21  1% for TTSSS/AAAAA-DD/AA)
(Fig. 8C).
The only other source of negative charge in the distal portion
of the C-terminal tail of FFA4, demonstrated above to be essen-
tial for arrestin-3 recruitment (Fig. 5A), is the Glu residue
Glu341. A gain of arrestin-3 interaction for the FFA4-345 trun-
cation compared with the inactive FFA4-340 truncation sug-
gested some role for residues 341–345. Interestingly, although
the E341A mutation alone did not significantly reduce arres-
tin-3 interaction comparedwith wild type,mutation of this res-
idue in addition to Asp348 andAsp355 to generate an EDD/AAA
mutant possessing no permanent negative charges did result in
a significant (p  0.001) reduction in arrestin-3 efficacy (69 
7% of wild type) (Fig. 8D). Thus, in combination, the three
acidic residues in the C-terminal tail of FFA4 provide structural
components that contribute to the effectiveness of arrestin-3
recruitment.
Finally, having demonstrated that Glu341 does appear to con-
tribute to FFA4/arrestin-3 interaction, we generated a further
mutant where E341A was incorporated into the TTSSS/
AAAA-DD/AAmutant to generate the TTSSS/AAAAA-EDD/
AAA form of FFA4 lacking all possible phosphorylation sites
and structural negative charges. This mutant resulted in a fur-
ther significant (p 0.001) reduction in efficacy from 21 1%
for TTSSS/AAAAA-DD/AA to only 11  3% for TTSSS/
AAAAA-EDD/AAA (Fig. 8E).
Summary: Arrestin-3 Interaction Relies on Both Phosphory-
lation and Structural Components—Removing phosphoryla-
tion sites (TTSSS/AAAAA) or the structural elements (EDD/
AAA) significantly reduced FFA4 interactionwith arrestin-3 by
58 and 31%, respectively (Fig. 9). Combining the phosphoryla-
tion site mutations with the structural mutations (TTSSS/
AAAA-EDD/AAA) reduced interaction with arrestin-3 almost
entirely (11% retention) (Fig. 9). Together, these results indicate
that phosphorylation and structural elements operate in com-
bination in a largely additive fashion to regulate agonist-medi-
ated arrestin-3 interactions with FFA4. Fig. 10 summarizes the
impact of the phosphorylation and structural components on
agonist-induced arrestin-3 recruitment to FFA4.
DISCUSSION
The realization that free fatty acids can act as biologically
activemolecules through a specific family ofGPCRs (19) has led
to the need to understand the in vivo biology of this receptor
family consisting of FFA1–4 as well as the modes of regulation
and signal transduction. Here we have focused on the FFA4
receptor, which is responsive to long and medium chain free
fatty acids (19) and reported to be involved in a range of biolog-
ical responses, including the regulation of glucose homeostasis
(11), lipogenesis (14), and inflammation (13). We report that,
like many GPCRs, FFA4 is rapidly phosphorylated following
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FIGURE 7. Hydroxyl amino acids that are targets for TUG-891-regulated
phosphorylation play an important but not exclusive role in agonist-
induced FFA4/arrestin-3 interactions. A, mutations of FFA4 that eliminate
three key sites of agonist-mediated phosphorylation (TSS/AAA) as well as a
combination of this with additional Ala mutation of Thr349 and Ser360 (TTSS/
AAAA and TSSS/AAAA, respectively) and a form of the receptor in which all
five hydroxyl amino acids were converted to Ala (TTSSS/AAAAAA) were used
in BRET-based arrestin-3 interaction studies in response to TUG-891 and com-
pared with wild type FFA4. B, the effects of individual mutation of each of
these hydroxyl amino acids in this assay. Error bars represent S.E.
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agonist occupation and that this post-translational modifica-
tion is involved in the recruitment of and interactionwith arres-
tin-3 and mediates arrestin-dependent processes, such as
receptor internalization. Importantly, we also identify struc-
tural elements within the C-terminal tail of the receptor that
operate in concert with the phosphorylation sites to provide
maximum recruitment of arrestin-3.
A recent report utilizing in silico phosphorylation site pre-
diction algorithms and site-directed mutagenesis identified
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FIGURE 8.Negatively charged residues in the C-terminal tail of FFA4 also contribute to the effectiveness of agonist-induced interactions with arres-
tin-3. A, arrestin-3 recruitment concentration-response curves to TUG-891 obtained from wild type FFA4 containing Ala replacement mutants for Asp348 or
Asp355 as well as a combined DD/AAmutant. B, similar experiments usingmutants generated from the TSS/AAA phosphodeficient form of FFA4. C, arrestin-3
interaction studies performedafter replacement of bothAsp residueswithAla in thebackgroundof themutant inwhich all five hydroxyl amino acids hadbeen
converted to Ala to generate the TTSSS/AAAAA-DD/AA mutant. D, TUG-891 arrestin-3 interaction studies carried out with the E341A mutation incorporated
into wild type or DD/AA (to make EDD/AAA) forms of FFA4. E, mutation E341A was also carried out in the form of FFA4 with all hydroxyl amino acids and Asp
residues converted to Ala (TTSSS/AAAAA-DD/AA) to generate TTSSS/AAAAA-EDD/AAA. The results with this mutant in the arrestin-3 interaction assay are
shown. Error bars represent S.E.
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FIGURE 9. Both structural elements and receptor phosphorylation deter-
mine arrestin-3 interaction with the free fatty acid receptor FFA4. A syn-
opsis of the key observations that both residues with fixed negative charge
and hydroxyl amino acids that becomephosphorylated in response to recep-
tor activation contribute to the efficacy of TUG-891-induced interactions
betweenFFA4andarrestin-3. TheTTSSS/AAAAA-EDD/AAAmutant is virtually
uncoupled from interacting with arrestin-3. Error bars represent S.E.
FIGURE10.Aschematic summarizing the contributionsmadeby receptor
phosphorylation and structural elements within the C-terminal tail to
the recruitment of arrestin-3 to FFA4.We demonstrate here that the resi-
dueswithin theC-terminal tail of FFA4downstreamof theputativepalmitoyl-
ated pair of cysteine residues are essential for the agonist-mediated interac-
tion of FFA4 with arrestin-3. Furthermore, using mass spectrometry and
mutagenesis, it was established that there are five phosphorylation sites
within the C-terminal tail of FFA4 arranged in two clusters. These phosphor-
ylation sites operate in concert with structural acidic residues to mediate the
recruitment of arrestin-3 to FFA4.
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three phosphorylation sites (Thr347, Ser350, and Ser357) in the C
terminus of FFA4 (20). Here, using a combination ofmass spec-
trometry andmutagenesis, we confirm that these three sites are
phosphorylated in response to agonist. We also identify two
additional sites in the C-terminal tail, Thr349 and Ser360, the
phosphorylation status of which is altered in response to ago-
nist treatment. Using a phosphospecific antibody that we gen-
erated based on the mass spectrometry studies we show both
that agonist-mediated phosphorylation at Thr347 and Ser350 is
rapid, occurring within minutes of receptor activation, and is
sustained and importantly that these same residues become
phosphorylated whether the receptor is expressed in either
CHO- or HEK293-based cell lines.
We further demonstrate that FFA4 can become phosphory-
lated by PKC in a manner that is sensitive to PKC inhibitors.
Despite this, agonist-regulated (homologous) phosphorylation
was not inhibited by PKC inhibitors, indicating that simple
feedback involving FFA4 activation of PKC and subsequent
receptor phosphorylation is not in operation at least in these
cells. Rather, our data support a recent study that reports that
agonist-mediated FFA4 phosphorylation occurs via a mem-
ber(s) of the G protein-coupled receptor kinase family (20). It
would seem, however, that although heterologous phosphory-
lation mediated by PKC activated by other Gq/11-coupled
receptors is possible the sites of this heterologous phosphory-
lation are not likely to be Thr347 and Ser350 as recently reported
(20) because our phosphospecific antibodies directed against
these sites did not detect any change in phosphorylation follow-
ing PKC activation.
Sequential removal of the five phosphorylation sites in the
C-terminal tail of FFA4 resulted in a progressive reduction in
agonist-mediated recruitment of arrestin-3. These data might
support the notion that it is the bulk negative charge on the
C-terminal tail that is responsible for driving receptor/arres-
tin-3 interactions and not necessarily the precise sites of phos-
phorylation. That this is not the case is indicated by the redun-
dant nature of phosphorylation at site Thr349, which appeared
not to contribute to arrestin-3 interaction. This phosphoryla-
tion site is located within a cluster of three sites (Thr347, Thr349,
and Ser350). It is possible that phosphorylation of only two of
these three sites is sufficient to provide the contribution to
arrestin-3 interaction provided by this cluster. This cluster of
phosphorylation sites then operates in concert with serines
Ser357 and Ser360 that make up the second cluster, together
driving full arrestin-3 recruitment. Hence, it appears for the
FFA4 receptor that it is not simply the bulk negative charge
contributed by phosphorylation at the C-terminal tail that is
important for arrestin-3 interaction but that the location of the
sites of phosphorylation also plays a role. Such a scenario has
been suggested for a number of other receptors, including the
M3 muscarinic receptor (21), 2-adrenergic receptor (22),
CXCR4 receptor (23), thyrotropin-releasing hormone receptor
(24, 25), and the somatostatin 2A receptor (26), leading to the
notion that there exists a phosphorylation bar code where the
specific sequence of phosphorylation sites encodes for the sig-
naling outcome of GPCRs (21, 22, 27). In the case of FFA4, it
appears that phosphorylation of at least two of the three sites in
cluster 1 (i.e.Thr347, Thr349, and Ser350) and both of the serines
in cluster 2 (Ser357 and Ser360) are required to be phosphory-
lated to give maximal arrestin-3 recruitment.
These phosphorylation sites appear to operate in concert
with structural elements consisting of the acidic residues
Glu341, Asp348, and Asp355 to recruit arrestin-3. Interestingly,
when all the phosphorylation sites were intact, the structural
elements appeared to play less of a role in arrestin-3 recruit-
ment. Hence, mutating residues Asp348 and Asp355 in a recep-
tor where the phosphorylation sites were intact had limited
impact on arrestin-3 recruitment. In this case, it is onlywhen all
three acidic residues were mutated that any impact on arres-
tin-3 recruitmentwas observed.However, in experiments using
mutant FFA4 receptors where phosphorylation sites were
removed, the structural elements appeared to play a more sig-
nificant role. This may have important functional implications
because recent x-ray crystal studies of the interaction of a phos-
phorylatedC-terminal peptide derived from theV2 vasopressin
receptor with an arrestin (arrestin-2 in this instance) have
shown that there aremultiple points of interaction between the
receptor peptide and the arrestin (28). It has been proposed that
the nature of these interactions determines the active confor-
mation of arrestin (22, 28), which in turn determines the signal-
ing outcome of the receptor-arrestin complex (22, 28). It is pos-
sible, therefore, that the structural elements in the C-tail of
FFA4 (Glu341, Asp348, and Asp355) directly interact with arres-
tin and work in combination with phosphorylation sites that
are regulated in response to agonist to recruit arrestin and pos-
sibly drive a particular arrestin conformation. Hence, the
nature of the active conformation of arrestin and therefore the
signaling outcome of the FFA4-arrestin complex might be
determined by the ensemble of FFA4 phosphorylation sites in
combination with the structural elements within the C-termi-
nal tail.
It was also noticeable as mutations and truncations were
introduced into the C-terminal tail of FFA4 that, as well as
resulting in reduced efficacy of TUG-891 in the receptor/arres-
tin-3 interaction assay, this was accompanied by a decrease in
agonist potency. This is despite the lack of effect on receptor/G
protein interactions and is likely to reflect that interaction
between aGPCRand an arrestin produces a high affinity, stable,
agonist-binding form (29). This may also provide the basis for
the slower association rate between such modified receptors
and arrestin-3 observed in the kinetic analyses. Although only
studied as a surrogate for the initiation of potential arrestin-3-
mediated signaling, it was also notable that such modifications
in FFA4 reduced but did not eliminate agonist-induced inter-
nalization of the receptor at least until the truncation was suf-
ficiently extensive (i.e. FFA4-340) that agonist-induced interac-
tion with the arrestin-3 construct was all but abrogated.
Understanding the combined role of FFA4 phosphorylation
and structural elements in the recruitment and possible activa-
tion of arrestins provides a basis for the design of FFA4 ligands
that might drive specific signaling outcomes. Such ligands have
been termed biased agonists (30–32) and have the potential to
drive specific physiological outcomes by preferentially engag-
ing a defined subset of receptor signaling pathways. At the pres-
ent time, there is very limited available synthetic ligand phar-
macology at FFA4, and as such, the arrestin-3-uncoupled form
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of the receptor produced in these studies may prove useful in
proof of concept studies for which signals in a physiological
setting are downstream of engagement with arrestins rather
than G protein-mediated pathways. The studies here show that
FFA4 signaling via Gq/11-mediated pathways is not dependent
on the phosphorylation status of the receptor, whereas arres-
tin-3 recruitment is regulated by FFA4 phosphorylation. At this
fundamental level, our data certainly point to the fact that an
FFA4 ligand showing stimulus bias toward receptor phosphor-
ylation/arrestin signaling would have potentially different
physiological outcomes from that of a ligand showingGprotein
bias. This might be important, for example, if FFA4 was being
targeted in inflammation, a response that appears in macro-
phages to be mediated by FFA4 signaling through arrestin-3
(13). It is possible, however, to extend the interpretation of our
studies and predict that a more subtle form of stimulus bias
might be possible. Ligands that drive different receptor phos-
phorylation patterns are beginning to emerge (21) and raise the
possibility that FFA4 ligands could be identified that generate
different phosphorylation ensembles (or bar codes). From the
data presented in this study, onemight predict that such ligands
would differentially drive arrestin recruitment and possibly dif-
ferential arrestin active conformations and in this way prefer-
entially activate signaling and physiological outcomes. As the
FFA4 receptor continues to be studied as a potential therapeu-
tic target for a number of disease indications, including type II
diabetes and inflammatory conditions (19), the design of
ligands showing stimulus bias (33) might prove important in
strategies to improve clinical efficacy and avoid adverse
responses. The data provided in this study suggest that design-
ing FFA4 ligands that can drive different patterns of receptor
phosphorylation might provide a mechanism by which differ-
ential signaling through arrestin-3 might be achieved.
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